お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
デフォルト表紙
市場調査レポート
商品コード
915399

突発性感音難聴(SSNHL)- 疫学予測 2028年

Sudden Sensorineural hearing loss (SSNHL) - Epidemiology Forecast - 2028

出版日: 受注後作成 | 発行: DelveInsight Business Research LLP | ページ情報: 英文 90 Pages | 納期: 2~10営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=111.33円
突発性感音難聴(SSNHL)- 疫学予測 2028年
出版日: 受注後作成
発行: DelveInsight Business Research LLP
ページ情報: 英文 90 Pages
納期: 2~10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

主要7カ国(米国、英国、ドイツ、フランス、イタリア、スペイン、日本)における突発性感音難聴(SSNHL)の2017年の罹患数は33万1,961人と推計されています。

当レポートでは、主要7カ国(米国、英国、ドイツ、フランス、イタリア、スペイン、日本)における突発性感音難聴(SSNHL)市場を調査し、疾病の概要や現行の治療法、アンメットニーズ、疫学的予測、市場規模、性別・年齢・重症度・性質・地域別の罹患数の推移と予測などをまとめています。

目次

第1章 重要洞察

第2章 突発性感音難聴(SSNHL)市場の概要

  • 突発性感音難聴(SSNHL)の分布(実数値)
  • 突発性感音難聴(SSNHL)の分布(予測値)

第3章 疾病背景と概要:突発性感音難聴(SSNHL)

  • イントロダクション
  • 兆候と症状
  • 病因
  • 病態生理
  • 診断

第4章 疫学と患者人口

  • 主な調査結果
  • 主要7カ国の突発性感音難聴(SSNHL)の罹患数
  • 主要7カ国の突発性感音難聴(SSNHL)の罹患数:国別
  • 米国
    • 仮定と理論的根拠
    • 突発性感音難聴(SSNHL)の罹患数
    • 突発性感音難聴(SSNHL)の罹患数:性別
    • 突発性感音難聴(SSNHL)の罹患数:年齢別
    • 突発性感音難聴(SSNHL)の罹患数:重症度別
    • 突発性感音難聴(SSNHL)の罹患数:性質別
  • EU5カ国
    • ドイツ
      • 仮定と理論的根拠
      • 突発性感音難聴(SSNHL)の罹患数
      • 突発性感音難聴(SSNHL)の罹患数:性別
      • 突発性感音難聴(SSNHL)の罹患数:年齢別
      • 突発性感音難聴(SSNHL)の罹患数:重症度別
      • 突発性感音難聴(SSNHL)の罹患数:性質別
    • フランス
    • イタリア
    • スペイン
    • 英国
  • 日本
    • 仮定と理論的根拠
    • 突発性感音難聴(SSNHL)の罹患数
    • 突発性感音難聴(SSNHL)の罹患数:性別
    • 突発性感音難聴(SSNHL)の罹患数:年齢別
    • 突発性感音難聴(SSNHL)の罹患数:重症度別
    • 突発性感音難聴(SSNHL)の罹患数:性質別

第5章 現行治療

  • 臨床診療ガイドライン

第6章 アンメットニーズ

第7章 市場の成長要因

第8章 市場の障壁

第9章 付録

第10章 DelveInsightのサービス内容

第11章 免責事項

第12章 DelveInsightについて

図表

List of Tables

  • Table 1: Identifiable Causes of Sudden Sensorineural Hearing Loss
  • Table 2: The main autoimmune target antigens in the inner ear
  • Table 3: Incident Cases of Sensorineural hearing loss in 7MM (2017-2028)
  • Table 4: Total Incident Cases of SSNHL in the US (2017-2028)
  • Table 5: Gender-Specific Incident Cases of SSNHL in the US (2017-2028)
  • Table 6: Age-Specific Cases of SSNHL in the US (2017-2028)
  • Table 7: Severity Specific Cases of SSNHL in the US (2017-2028)
  • Table 8: Nature Specific Cases of SSNHL in the US (2017-2028)
  • Table 9: Total Incident Cases of SSNHL in Germany (2017-2028)
  • Table 10: Gender-Specific Cases of SSNHL in Germany (2017-2028)
  • Table 11: Age-Specific Cases of SSNHL in Germany (2017-2028)
  • Table 12: Severity Specific Cases of SSNHL in Germany (2017-2028)
  • Table 13: Nature Specific Cases of SSNHL in Germany (2017-2028)
  • Table 14: Total Incident Cases of SSNHL in France (2017-2028)
  • Table 15: Gender-Specific Cases of SSNHL in France (2017-2028)
  • Table 16: Age-Specific Cases of SSNHL in France (2017-2028)
  • Table 17: Severity Specific Cases of SSNHL in France (2017-2028)
  • Table 18: Nature Specific Cases of SSNHL in France (2017-2028)
  • Table 19: Total Incident Cases of SSNHL in Italy (2017-2028)
  • Table 20: Gender-Specific Cases of SSNHL in Italy (2017-2028)
  • Table 21: Age-Specific Cases of SSNHL in Italy (2017-2028)
  • Table 22: Severity Specific Cases of SSNHL in Italy (2017-2028)
  • Table 23: Nature Specific Cases of SSNHL in Italy (2017-2028)
  • Table 24: Total Incident Cases of SSNHL in Spain (2017-2028)
  • Table 25: Gender-Specific Cases of SSNHL in Spain (2017-2028)
  • Table 26: Age-Specific Cases of SSNHL in Spain (2017-2028)
  • Table 27: Severity Specific Cases of SSNHL in Spain (2017-2028)
  • Table 28: Nature Specific Cases of SSNHL in Spain (2017-2028)
  • Table 29: Total Incident Cases of SSNHL in the UK (2017-2028)
  • Table 30: Gender-Specific Cases of SSNHL in the UK (2017-2028)
  • Table 31: Age-Specific Cases of SSNHL in the UK (2017-2028)
  • Table 32: Severity Specific Cases of SSNHL in the UK (2017-2028)
  • Table 33: Nature Specific Cases of SSNHL in the UK (2017-2028)
  • Table 34: Total Incident Cases of SSNHL in Japan (2017-2028)
  • Table 35: Gender-Specific Incident Cases of SSNHL in Japan (2017-2028)
  • Table 36: Age-Specific Cases of SSNHL in the US (2017-2028)
  • Table 37: Severity Specific Cases of SSNHL in Japan (2017-2028)
  • Table 38: Nature Specific Cases of SSNHL in Japan (2017-2028)

List of Figures

  • Figure 1: Signs and Symptoms of Sensorineural hearing loss
  • Figure 2: The distribution of immune cells in the inner ear when the immune response is initiated
  • Figure 3: The mechanisms of inner ear damage by the type II-IV allergic reactions
  • Figure 4: WHO grading
  • Figure 5: Incident Cases of Sensorineural hearing loss in 7MM (2017-2028)
  • Figure 6: Total Incident Cases of SSNHL in the US (2017-2028)
  • Figure 7: Gender-Specific Cases of SSNHL in the US (2017-2028)
  • Figure 8: Age-Specific Cases of SSNHL in the US (2017-2028)
  • Figure 9: Severity Specific Cases of SSNHL in the US (2017-2028)
  • Figure 10: Nature Specific Cases of SSNHL in the US (2017-2028)
  • Figure 11: Total Incident Cases of SSNHL in Germany (2017-2028)
  • Figure 12: Gender-Specific Cases of SSNHL in Germany (2017-2028)
  • Figure 13: Age-Specific Cases of SSNHL in Germany (2017-2028)
  • Figure 14: Severity Specific Cases of SSNHL in Germany (2017-2028)
  • Figure 15: Nature Specific Cases of SSNHL in Germany (2017-2028)
  • Figure 16: Total Incident Cases of SSNHL in France (2017-2028)
  • Figure 17: Gender-Specific Cases of SSNHL in France (2017-2028)
  • Figure 18: Age-Specific Cases of SSNHL in France (2017-2028)
  • Figure 19: Severity Specific Cases of SSNHL in France (2017-2028)
  • Figure 20: Nature Specific Cases of SSNHL in France (2017-2028)
  • Figure 21: Total Incident Cases of SSNHL in Italy (2017-2028)
  • Figure 22: Gender-Specific Cases of SSNHL in Italy (2017-2028)
  • Figure 23: Age-Specific Cases of SSNHL in Italy (2017-2028)
  • Figure 24: Severity Specific Cases of SSNHL in Italy (2017-2028)
  • Figure 25: Nature Specific Cases of SSNHL in Italy (2017-2028)
  • Figure 26: Total Incident Cases of SSNHL in Spain (2017-2028)
  • Figure 27: Gender-Specific Cases of SSNHL in Spain (2017-2028)
  • Figure 28: Age-Specific Cases of SSNHL in Spain (2017-2028)
  • Figure 29: Severity Specific Cases of SSNHL in Spain (2017-2028)
  • Figure 30: Nature Specific Cases of SSNHL in Spain (2017-2028)
  • Figure 31: Total Incident Cases of SSNHL in the UK (2017-2028)
  • Figure 32: Gender-Specific Cases of SSNHL in the UK (2017-2028)
  • Figure 33: Age-Specific Cases of SSNHL in the UK (2017-2028)
  • Figure 34: Severity Specific Cases of SSNHL in the UK (2017-2028)
  • Figure 35: Nature Specific Cases of SSNHL in the UK (2017-2028)
  • Figure 36: Total Incident Cases of SSNHL in Japan (2017-2028)
  • Figure 37: Gender-Specific Cases of SSNHL in Japan (2017-2028)
  • Figure 38: Age-Specific Cases of SSNHL in Japan (2017-2028)
  • Figure 39: Severity Specific Cases of SSNHL in Japan (2017-2028)
  • Figure 40: Nature Specific Cases of SSNHL in Japan (2017-2028)
  • Figure 41: Unmet Needs
  • Figure 42:Market Drivers
  • Figure 43:Market Barriers
目次
Product Code: DIEI0389

DelveInsight's 'Sudden Sensorineural hearing loss (SSNHL)-Epidemiology Forecast-2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology trends of Sudden Sensorineural hearing loss in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2028

Sudden Sensorineural hearing loss - Disease Understanding

Sensorineural hearing loss (SNHL) is the most common type of hearing loss, referred colloquially as "nerve hearing loss", which indicates abnormal functioning of the cochlea, auditory nerve, or higher aspects of central auditory perception or processing. Sudden Sensorineural hearing loss (SSNHL) is a subset of SHL that is sensorineural in nature, occurs within a 72-h window, and meets certain audiometric criteria. In major parts of the world, Sudden Sensorineural hearing loss (SSNHL) is most often defined as "Sensorineural hearing loss of 30 dB or greater over at least three contiguous audiometric frequencies occurring over 72 h". In 2012, The Research Committee of the Ministry of Health and Welfare for Acute Profound Deafness in Japan also accepted this definition.

It is a symptom of cochlear injury characterized by a sudden onset and, within a few hours, reaches its maximum peak. It is also called as Labyrinthine hearing loss. Any age group may be affected, but the peak incidence occurs in the 5th or 6th decade of life. The most common presentation is a unilateral hearing loss upon awakening or when attempting to use the affected ear. Bilateral involvement is rare, and simultaneous bilateral involvement is very infrequent.

Sudden Sensorineural hearing loss - Epidemiology

The Sudden Sensorineural hearing loss epidemiology division provides insights about historical and current incident pool and forecasted trends for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders (KOL).

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Incident cases of SSNHL, Gender-Specific cases of SSNHL, Age-Specific cases of SSNHL, Severity Specific cases of SSNHL, and Nature Specific cases of SSNHL) scenario of Sudden Sensorineural Hearing loss in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017 to 2028.

According to DelveInsight, the total Incident cases of Sudden Sensorineural hearing loss (SSNHL) in the 7MM was found to be 331,961 in 2017. The incidence of Sudden Sensorineural hearing loss in the 7MM is expected to increase during the study period of 2017-2028.

Among 7MM, the EU-5 has the highest incident cases of Sudden Sensorineural hearing loss with about 167,008 cases in 2017. Among EU-5 countries, Germany had the highest number of incident cases with approximately 128,950 cases, followed by France with approximately 11,744 cases in 2017. Spain had the least number of incident cases, while in Japan, the incident cases of Sudden Sensorineural hearing loss was found to be approximately 77,009.

Sudden Sensorineural hearing loss Report Insights

  • The report covers a descriptive overview of Sudden Sensorineural hearing loss, explaining its causes, risk factors, pathophysiology, and diagnosis.
  • Comprehensive insight has been provided into the epidemiology Sudden Sensorineural hearing loss in the 7MM countries covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • Assesses growth opportunities in 7MM countries with respect to the patient population.

Sudden Sensorineural hearing loss Report Key Strengths

  • 10-Year Forecast
  • 7MM Coverage
  • Total Incident case of Sudden Sensorineural hearing loss
  • Total Incident case of Sudden Sensorineural hearing loss by Gender-Specific Cases
  • Total Incident case of Sudden Sensorineural hearing loss by Age Specific Cases
  • Total Incident case of Sudden Sensorineural hearing loss by Severity Specific Cases
  • Total Incident case of Sudden Sensorineural hearing loss by Nature Specific Cases

Sudden Sensorineural hearing loss Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles

Key Benefits

  • Key assessments
  • Disease Risk & Burden
  • Risk of disease by Grade

Table of Contents

1. Key Insights

2. Sudden Sensorineural hearing loss (SSNHL): Market Overview at a Glance

  • 2.1. Patient Share (%) Distribution of SSNHL in 2017
  • 2.2. Patient Share (%) Distribution of SSNHL in 2028

3. Disease Overview: Sensorineural hearing loss (SNHL)

  • 3.1. Introduction
  • 3.2. Signs and Symptoms
  • 3.3. Etiology
  • 3.4. Pathophysiology
  • 3.5. Diagnosis

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. 7MM Incident Cases of Sudden Sensorineural hearing loss
  • 4.3. Country Wise-Epidemiology of Sensorineural hearing loss
  • 4.4. United States
    • 4.4.1. Assumptions and Rationale
    • 4.4.2. Total Incident cases of SSNHL in the US
    • 4.4.3. Gender-Specific cases of SSNHL in the US
    • 4.4.4. Age-Specific Cases of SSNHL in the US
    • 4.4.5. Severity Specific cases of SSNHL in the US
    • 4.4.6. Nature Specific cases of SSNHL in the US
  • 4.5. EU5
    • 4.5.1. Assumptions and Rationale
  • 4.6. Germany
    • 4.6.1. Total Incident cases of SSNHL in Germany
    • 4.6.2. Gender-Specific cases of SSNHL in Germany
    • 4.6.3. Age-Specific Cases of SSNHL in Germany
    • 4.6.4. Severity Specific cases of SSNHL in Germany
    • 4.6.5. Nature Specific cases of SSNHL in Germany
  • 4.7. France
    • 4.7.1. Total Incident cases of SSNHL in France
    • 4.7.2. Gender-Specific cases of SSNHL in France
    • 4.7.3. Age-Specific Cases of SSNHL in France
    • 4.7.4. Severity Specific cases of SSNHL in France
    • 4.7.5. Nature Specific cases of SSNHL in France
  • 4.8. Italy
    • 4.8.1. Total Incident cases of SSNHL in Italy
    • 4.8.2. Gender-Specific cases of SSNHL in Italy
    • 4.8.3. Age-Specific Cases of SSNHL in Italy
    • 4.8.4. Severity Specific cases of SSNHL in Italy
    • 4.8.5. Nature Specific cases of SSNHL in Italy
  • 4.9. Spain
    • 4.9.1. Total Incident cases of SSNHL in Spain
    • 4.9.2. Gender-Specific cases of SSNHL in Spain
    • 4.9.3. Age-Specific Cases of SSNHL in Spain
    • 4.9.4. Severity Specific cases of SSNHL in Spain
    • 4.9.5. Nature Specific cases of SSNHL in Spain
  • 4.10. United Kingdom
    • 4.10.1. Total Incident cases of SSNHL in the UK
    • 4.10.2. Gender-Specific cases of SSNHL in the UK
    • 4.10.3. Age-Specific Cases of SSNHL in the UK
    • 4.10.4. Severity Specific cases of SSNHL in the UK
    • 4.10.5. Nature Specific cases of SSNHL in the UK
  • 4.11. Japan
    • 4.11.1. Assumptions and Rationale
    • 4.11.2. Total Incident cases of SSNHL in Japan
    • 4.11.3. Gender-Specific cases of SSNHL in Japan
    • 4.11.4. Age-Specific Cases of SSNHL in Japan
    • 4.11.5. Severity Specific cases of SSNHL in Japan
    • 4.11.6. Nature Specific cases of SSNHL in Japan

5. Current Treatment Practices

  • 5.1. Clinical Practice Guideline: Sudden Hearing Loss

6. Unmet Needs

7. Market Drivers

8. Market Barriers

9. Appendix

  • 9.1. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.